Boston Scientific Shares Rise on Updated Guidance as it Navigates Challenges -- WSJ

Dow Jones04-23

By Peter Loftus

Medical-device maker Boston Scientific slashed its forecast of full-year 2026 revenue Wednesday, citing softer-than-expected sales in areas like kidney-stone devices and its Watchman heart-rhythm device.

Yet the company's share price surged 8% Wednesday, on pace for its largest percent increase since March 2020.

It turns out investors were already expecting a guidance cut and the revised, lower targets now appear achievable. What's more, the company said it plans to buy back about $2 billion of its shares in the second quarter, which Evercore ISI analyst Vijay Kumar said was a sign of confidence.

Boston Scientific, which makes a range of devices for heart disease and other conditions, was riding high through late last year, buoyed by the success of its new Farapulse cardiac ablation system.

But the stock is down more than 30% year-to-date on a slowdown in its ablation business and Watchman. Investors have questioned whether Boston Scientific could hit its initial targets of full-year sales growth of up to 11.5%.

On Wednesday, the company lowered that target to sales growth of up to 8.5%. Analysts said the new guidance amounted to a reset, and appears conservative enough to leave room for Boston Scientific to exceed it.

This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).

(END) Dow Jones Newswires

April 22, 2026 15:02 ET (19:02 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629024073?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-23 03:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629024073","market":"us","top_or_hot":-1,"title":"Boston Scientific Shares Rise on Updated Guidance as it Navigates Challenges -- WSJ","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n       By Peter Loftus \n</p>\n<p>\n     Medical-device maker Boston Scientific slashed its forecast of full-year 2026 revenue Wednesday, citing softer-than-expected sales in areas like kidney-stone devices and its Watchman heart-rhythm device. \n</p>\n<p>\n     Yet the company's share price surged 8% Wednesday, on pace for its largest percent increase since March 2020. \n</p>\n<p>\n     It turns out investors were already expecting a guidance cut and the revised, lower targets now appear achievable. What's more, the company said it plans to buy back about $2 billion of its shares in the second quarter, which <a href=\"https://laohu8.com/S/EVR\">Evercore</a> ISI analyst Vijay Kumar said was a sign of confidence. \n</p>\n<p>\n     Boston Scientific, which makes a range of devices for heart disease and other conditions, was riding high through late last year, buoyed by the success of its new Farapulse cardiac ablation system. \n</p>\n<p>\n     But the stock is down more than 30% year-to-date on a slowdown in its ablation business and Watchman. Investors have questioned whether Boston Scientific could hit its initial targets of full-year sales growth of up to 11.5%. \n</p>\n<p>\n     On Wednesday, the company lowered that target to sales growth of up to 8.5%. Analysts said the new guidance amounted to a reset, and appears conservative enough to leave room for Boston Scientific to exceed it. \n</p>\n<p>\n       This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 22, 2026 15:02 ET (19:02 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Boston Scientific Shares Rise on Updated Guidance as it Navigates Challenges -- WSJ</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBoston Scientific Shares Rise on Updated Guidance as it Navigates Challenges -- WSJ\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-23 03:02</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n       By Peter Loftus \n</p>\n<p>\n     Medical-device maker Boston Scientific slashed its forecast of full-year 2026 revenue Wednesday, citing softer-than-expected sales in areas like kidney-stone devices and its Watchman heart-rhythm device. \n</p>\n<p>\n     Yet the company's share price surged 8% Wednesday, on pace for its largest percent increase since March 2020. \n</p>\n<p>\n     It turns out investors were already expecting a guidance cut and the revised, lower targets now appear achievable. What's more, the company said it plans to buy back about $2 billion of its shares in the second quarter, which <a href=\"https://laohu8.com/S/EVR\">Evercore</a> ISI analyst Vijay Kumar said was a sign of confidence. \n</p>\n<p>\n     Boston Scientific, which makes a range of devices for heart disease and other conditions, was riding high through late last year, buoyed by the success of its new Farapulse cardiac ablation system. \n</p>\n<p>\n     But the stock is down more than 30% year-to-date on a slowdown in its ablation business and Watchman. Investors have questioned whether Boston Scientific could hit its initial targets of full-year sales growth of up to 11.5%. \n</p>\n<p>\n     On Wednesday, the company lowered that target to sales growth of up to 8.5%. Analysts said the new guidance amounted to a reset, and appears conservative enough to leave room for Boston Scientific to exceed it. \n</p>\n<p>\n       This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 22, 2026 15:02 ET (19:02 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0353189763.USD","symbol_name":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2629024073","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629024073","pubTimestamp":1776884520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Medical-device maker Boston Scientific slashed its forecast of full-year 2026 revenue Wednesday, citing softer-than-expected sales in areas like kidney-stone devices and its Watchman heart-rhythm device.Yet the company's share price surged 8% Wednesday, on pace for its largest percent increase since March 2020.It turns out investors were already expecting a guidance cut and the revised, lower targets now appear achievable. What's more, the company said it plans to buy back about $2 billion of its shares in the second quarter, which Evercore ISI analyst Vijay Kumar said was a sign of confidence.Boston Scientific, which makes a range of devices for heart disease and other conditions, was riding high through late last year, buoyed by the success of its new Farapulse cardiac ablation system.But the stock is down more than 30% year-to-date on a slowdown in its ablation business and Watchman. Investors have questioned whether Boston Scientific could hit its initial targets of full-year sales","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU0823417653.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BSX":"波士顿科学","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0122379950.USD":"贝莱德世界健康科学A2","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1548497426.USD":"安联环球人工智能AT Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","BK4581":"高盛持仓","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0238689110.USD":"贝莱德环球动力股票基金","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC"},"translate_title":"波士顿科学公司股价因更新指引而上涨，以应对挑战——《华尔街日报》","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1.5},"content_text":"By Peter Loftus \n\n\n     Medical-device maker Boston Scientific slashed its forecast of full-year 2026 revenue Wednesday, citing softer-than-expected sales in areas like kidney-stone devices and its Watchman heart-rhythm device. \n\n\n     Yet the company's share price surged 8% Wednesday, on pace for its largest percent increase since March 2020. \n\n\n     It turns out investors were already expecting a guidance cut and the revised, lower targets now appear achievable. What's more, the company said it plans to buy back about $2 billion of its shares in the second quarter, which Evercore ISI analyst Vijay Kumar said was a sign of confidence. \n\n\n     Boston Scientific, which makes a range of devices for heart disease and other conditions, was riding high through late last year, buoyed by the success of its new Farapulse cardiac ablation system. \n\n\n     But the stock is down more than 30% year-to-date on a slowdown in its ablation business and Watchman. Investors have questioned whether Boston Scientific could hit its initial targets of full-year sales growth of up to 11.5%. \n\n\n     On Wednesday, the company lowered that target to sales growth of up to 8.5%. Analysts said the new guidance amounted to a reset, and appears conservative enough to leave room for Boston Scientific to exceed it. \n\n\n       This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage). \n\n\n  (END) Dow Jones Newswires\n\n\n  April 22, 2026 15:02 ET (19:02 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629024073","isCrawlerRequest":true}